Overview of Genetic Technologies Limited's Entitlement Offer Results and Closing

Genetic Technologies Limited (ASX:GTG) successfully closed its Entitlement Offer on Monday, 9 September 2024, raising $324,648 from eligible shareholders. The company received applications for 8,116,205 shares at an issue price of $0.04 with one free attaching option, indicating a strong level of participation. The total shortfall under the Entitlement Offer is 88,828,626 New Shares at an issue price of $0.04 with one free attaching option, amounting to a shortfall of up to $3,553,145.

Executive Commentary on Entitlement Offer Results

The Board of Genetic Technologies expresses gratitude to shareholders for their high participation rates and ongoing support. The company is actively working with brokers to place the shortfall, and significant interest has already been received. The Board also notes that no allotments will occur until the minimum of $2 million in applications is received, and further updates on the progress of the Shortfall Offer will be provided to the ASX market.

Summary of Entitlement Offer Results and Outlook

Genetic Technologies Limited (ASX:GTG) successfully closed its Entitlement Offer, raising $324,648 from eligible shareholders. The company received strong participation, with applications for 8,116,205 shares at an issue price of $0.04 with one free attaching option. The total shortfall under the Entitlement Offer is 88,828,626 New Shares at an issue price of $0.04 with one free attaching option, amounting to a shortfall of up to $3,553,145. The company has extended the period to receive Shortfall Commitments and is actively working with brokers to place the shortfall. Genetic Technologies expresses gratitude to shareholders for their support and participation, and the company's proprietary risk stratification platform continues to drive the development of risk assessment products in oncology, cardiovascular, and metabolic diseases.